DefinitionThis section has been translated automatically.
Antiretrovirally active substance for the treatment of HIV infection. Inhibitor of the HIV integrase ( strand transfer inhibitor). Chemically, it is a compound reminiscent of quinolone antibiotics, but has no antibacterial activity and no quinolone-associated side effects.
Dosage and method of useThis section has been translated automatically.
According to ongoing phase III studies: 1-2 times/day 50-125 mg each in combination with 100 mg ritonavir and/or an active protease inhibitor.
Undesirable effectsThis section has been translated automatically.
Rarely nausea, dizziness, headaches, diarrhoea and fever. Due to the study situation no long-term data are available.
Note(s)This section has been translated automatically.
Remember! Currently (as of 6/2009) Elvitegravir is only available via an Expanded Access Program for patients with viral resistance to at least one drug of the substance classes NRTI, NNRTI and PI!
Prof. Dr. med. Peter Altmeyer